0

Close
 
Upcoming Allied Market Research
2023
Nifedipine Market

Nifedipine Market

by Product (Nifedipine Controlled Release Tablets, Nifedipine Extended Action Tablets) and by Application (Primary Pulmonary Hypertension, Heart Failure, Raynauds Syndrome, Cephalagra, Bronchial Asthma, Premature Labor): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A03658
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Nifedipine Market

Request Now !

Nifedipine is a drug that belongs to the class of calcium channel blocker, which interrupts the movement of calcium in the walls of the arteries. Nifedipine is used specifically to treat hypertension, arrhythmias, and angina. In addition, it has several other therapeutical applications such as ryanoids syndrome, cephalagra, and others.

Factors such as increase in geriatric population, healthcare expenditure, incidence of chronic diseases such as heart failure, arrhythmias, & hypertension, and healthcare awareness fuel the growth of the market. However, stringent government regulations and side-effects of the drugs such as hypotension, gastric ulcers, and congestive heart failure hinder the market growth. Ongoing R&D activities are anticipated to present new growth opportunities.

The market is segmented on the basis of product, application, and region. By product, the market is bifurcated into nifedipine controlled release tablets and nifedipine extended release tablets. Based on application, the market is categorized into primary pulmonary hypertension, heart failure, ryanoids disease, cephalagra, bronchial asthma, and premature labor. By region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits

  • The study provides an in-depth analysis of the nifedipine market, with current trends and future estimations to elucidate investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • The report provides a quantitative analysis to help stakeholders to capitalize on prevailing market opportunities in terms of value.
  • Extensive analysis of different segments helps understand various products of the market.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

 Nifedipine Market Report Highlights

Aspects Details
By Product
  • Nifedipine Controlled Release Tablets
  • Nifedipine Extended Action Tablets
By Application
  • Primary Pulmonary Hypertension
  • Heart Failure
  • Raynauds Syndrome
  • Cephalagra
  • Bronchial Asthma
  • Premature Labor
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Merck and Co., Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Pfizer Inc., F. Hoffmann La Roche AG, Vectura Group plc, Novartis AG, Abbott Laboratories
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: NIFEDIPINE MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Nifedipine Controlled Release Tablets

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Nifedipine Extended Action Tablets

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: NIFEDIPINE MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Primary Pulmonary Hypertension

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Heart Failure

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Raynauds Syndrome

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Cephalagra

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Bronchial Asthma

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Premature Labor

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: NIFEDIPINE MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Nifedipine Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Nifedipine Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Nifedipine Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Nifedipine Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Nifedipine Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Nifedipine Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Nifedipine Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Nifedipine Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Nifedipine Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Nifedipine Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Nifedipine Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Nifedipine Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Nifedipine Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Nifedipine Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Nifedipine Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Nifedipine Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Nifedipine Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Nifedipine Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Nifedipine Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Nifedipine Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Nifedipine Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Nifedipine Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Nifedipine Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Nifedipine Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Nifedipine Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. GlaxoSmithKline Plc

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Novartis AG

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Merck And Co., Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Abbott Laboratories

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Boehringer Ingelheim GmbH

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. AstraZeneca Plc

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. F. Hoffmann La Roche AG

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Teva Pharmaceutical Industries Ltd.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Vectura Group Plc

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Pfizer Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NIFEDIPINE MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL NIFEDIPINE MARKET FOR NIFEDIPINE CONTROLLED RELEASE TABLETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL NIFEDIPINE MARKET FOR NIFEDIPINE EXTENDED ACTION TABLETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL NIFEDIPINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL NIFEDIPINE MARKET FOR PRIMARY PULMONARY HYPERTENSION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL NIFEDIPINE MARKET FOR HEART FAILURE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL NIFEDIPINE MARKET FOR RAYNAUDS SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL NIFEDIPINE MARKET FOR CEPHALAGRA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL NIFEDIPINE MARKET FOR BRONCHIAL ASTHMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL NIFEDIPINE MARKET FOR PREMATURE LABOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL NIFEDIPINE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA NIFEDIPINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. U.S. NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 16. U.S. NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. CANADA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 18. CANADA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 20. MEXICO NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE NIFEDIPINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. FRANCE NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. GERMANY NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. GERMANY NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. ITALY NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. ITALY NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. SPAIN NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. UK NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 33. UK NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. RUSSIA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 35. RUSSIA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. REST OF EUROPE NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. REST OF EUROPE NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC NIFEDIPINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 39. ASIA-PACIFIC NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. CHINA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. CHINA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. JAPAN NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 44. JAPAN NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. INDIA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. INDIA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. SOUTH KOREA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. AUSTRALIA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 50. AUSTRALIA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. THAILAND NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. THAILAND NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. MALAYSIA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 54. MALAYSIA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. INDONESIA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. INDONESIA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA NIFEDIPINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 60. LAMEA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. BRAZIL NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 63. BRAZIL NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH AFRICA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH AFRICA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. SAUDI ARABIA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. SAUDI ARABIA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. UAE NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. UAE NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. ARGENTINA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. ARGENTINA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. REST OF LAMEA NIFEDIPINE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 73. REST OF LAMEA NIFEDIPINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 75. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 76. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 77. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 78. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 81. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 83. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 85. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 86. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 87. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 88. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 90. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 91. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 92. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 93. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
  • TABLE 95. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
  • TABLE 96. BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
  • TABLE 97. BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
  • TABLE 98. BOEHRINGER INGELHEIM GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 100. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 101. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 102. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 103. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. F. HOFFMANN LA ROCHE AG: KEY EXECUTIVES
  • TABLE 105. F. HOFFMANN LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 106. F. HOFFMANN LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 107. F. HOFFMANN LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 108. F. HOFFMANN LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 110. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 111. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. VECTURA GROUP PLC: KEY EXECUTIVES
  • TABLE 115. VECTURA GROUP PLC: COMPANY SNAPSHOT
  • TABLE 116. VECTURA GROUP PLC: OPERATING SEGMENTS
  • TABLE 117. VECTURA GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 118. VECTURA GROUP PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. PFIZER INC.: KEY EXECUTIVES
  • TABLE 120. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 121. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 122. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 123. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NIFEDIPINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NIFEDIPINE MARKET
  • FIGURE 3. SEGMENTATION NIFEDIPINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NIFEDIPINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNIFEDIPINE MARKET
  • FIGURE 11. NIFEDIPINE MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. NIFEDIPINE MARKET FOR NIFEDIPINE CONTROLLED RELEASE TABLETS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NIFEDIPINE MARKET FOR NIFEDIPINE EXTENDED ACTION TABLETS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. NIFEDIPINE MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. NIFEDIPINE MARKET FOR PRIMARY PULMONARY HYPERTENSION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. NIFEDIPINE MARKET FOR HEART FAILURE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. NIFEDIPINE MARKET FOR RAYNAUDS SYNDROME, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. NIFEDIPINE MARKET FOR CEPHALAGRA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. NIFEDIPINE MARKET FOR BRONCHIAL ASTHMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. NIFEDIPINE MARKET FOR PREMATURE LABOR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: NIFEDIPINE MARKET
  • FIGURE 27. Top player positioning, 2022
  • FIGURE 28. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. BOEHRINGER INGELHEIM GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. F. HOFFMANN LA ROCHE AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. F. HOFFMANN LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. F. HOFFMANN LA ROCHE AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. VECTURA GROUP PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. VECTURA GROUP PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. VECTURA GROUP PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Nifedipine Market

Start reading.
This Report and over 68,094+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers